Colin McCracken's Insider Trades & SAST Disclosures
Colin McCracken's most recent trade in Standard BioTools Inc was a trade of 3,740 Common Stock done at an average price of $3.6 . Disclosure was reported to the exchange on Feb. 22, 2022.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Colin McCracken.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.62 per share. | 22 Feb 2022 | 3,740 | 65,103 (0%) | 0% | 3.6 | 13,539 | Common Stock |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 2,598 | 68,843 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 2,598 | 12,989 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 2,391 | 19,126 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 2,391 | 66,245 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 1,531 | 7,657 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2022 | 1,531 | 63,854 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2022 | 50,000 | 50,000 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.49 per share. | 20 Nov 2021 | 3,530 | 62,323 (0%) | 0% | 4.5 | 15,850 | Common Stock |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2021 | 2,598 | 15,587 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2021 | 2,598 | 61,932 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2021 | 2,390 | 65,853 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2021 | 2,390 | 21,517 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2021 | 1,531 | 63,463 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2021 | 1,531 | 9,188 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.53 per share. | 20 Aug 2021 | 3,523 | 59,334 (0%) | 0% | 6.5 | 23,005 | Common Stock |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2021 | 2,597 | 58,935 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2021 | 2,597 | 18,185 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2021 | 2,391 | 23,907 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2021 | 2,391 | 62,857 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2021 | 1,531 | 60,466 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2021 | 1,531 | 10,719 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2021 | 60,000 | 60,000 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2021 | 60,000 | 92,425 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.52 per share. | 20 May 2021 | 36,087 | 56,338 (0%) | 0% | 5.5 | 199,200 | Common Stock |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2021 | 2,598 | 20,782 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2021 | 2,598 | 28,503 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2021 | 2,390 | 26,298 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2021 | 2,390 | 32,425 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2021 | 1,532 | 12,250 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2021 | 1,532 | 30,035 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Apr 2021 | 65,792 | 65,792 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2021 | 9,562 | 33,777 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2021 | 9,562 | 28,688 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.12 per share. | 20 Feb 2021 | 7,872 | 25,905 (0%) | 0% | 6.1 | 48,177 | Common Stock |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2021 | 2,598 | 23,380 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2021 | 2,598 | 22,684 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2021 | 1,531 | 24,215 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2021 | 1,531 | 13,782 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2020 | 2,598 | 25,978 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2020 | 2,598 | 20,254 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.28 per share. | 20 Nov 2020 | 1,699 | 20,086 (0%) | 0% | 6.3 | 10,670 | Common Stock |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2020 | 1,531 | 21,785 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Nov 2020 | 1,531 | 15,313 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2020 | 2,597 | 17,823 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2020 | 2,597 | 28,576 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.91 per share. | 20 Aug 2020 | 1,698 | 17,656 (0%) | 0% | 7.9 | 13,431 | Common Stock |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2020 | 1,531 | 19,354 (0%) | 0% | 0 | Common Stock | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Aug 2020 | 1,531 | 16,844 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2020 | 120,000 | 120,000 | - | - | Restricted Stock Units | |
| Standard BioTools Inc | Colin McCracken | Chief Commercial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.39 per share. | 20 May 2020 | 6,797 | 15,226 (0%) | 0% | 4.4 | 29,805 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges